| Field | Specification |
|---|---|
| Target | |
| Alternative names | Transcription factor MafF; U-Maf; V-maf musculoaponeurotic fibrosarcoma oncogene homolog F; MAFF |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human MAFF recombinant protein (Position: M1-L37). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes transcription factor MafF in human samples and is validated for Western blot, IHC, ICC/IF, flow cytometry and ELISA. The predicted molecular weight is 17.8 kDa, and the supplier reports an observed band at about 18 kDa.
MafF is a small Maf protein, a basic leucine zipper factor that lacks a transactivation domain. Small Mafs repress transcription as homodimers but activate genes when paired with CNC-family partners such as NRF2 at antioxidant response elements, so MafF is studied in oxidative stress responses and inflammation.
| Target | Transcription factor MafF (gene MAFF; UniProt Q9ULX9, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 17.8 kDa |
| Observed MW | 18 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
| ELISA | 0.1–0.5 µg/mL |
Samples with a confirmed band (WB): human HepG2 cells, human U2OS cells, human PC-3 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human esophageal squamous carcinoma tissue, human placenta tissue, human lung cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A431 cells.
Samples with a confirmed signal (flow cytometry): A431 cells.
Immunogen
Recombinant human MAFF fragment (Met1–Leu37), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places transcription factor MafF in the nucleus. Tissue expression noted by UniProt (human): Expressed in the term myometrium and kidney. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Jianai Ji et al. (2023) ARE-PROTACs Enable Co-degradation of an Nrf2–MafG Heterodimer. Journal of Medicinal Chemistry. 10.1021/acs.jmedchem.2c01909
Jian’ai Ji et al. (2024) Discovery of a NCOA4 Degrader for Labile Iron-Dependent Ferroptosis Inhibition. Journal of Medicinal Chemistry. 10.1021/acs.jmedchem.4c00403
